Form 4: Arcellx Director Kavita Patel Granted Stock Options in Routine Compensation

Arcellx, Inc. Director Kavita Patel was granted 9,174 stock options with an exercise price of $63.68, vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders.

Summary

• Kavita Patel, a Director of Arcellx, Inc. (ACLX), was granted 9,174 stock options.
• The transaction date for this grant was May 29, 2025.
• The exercise price for these stock options is $63.68 per share.
• The options are scheduled to vest 100% on the earlier of May 29, 2026, or the next annual meeting of stockholders.
• Vesting is contingent upon Ms. Patel's continued service as a Service Provider, as defined in the 2022 Equity Incentive Plan.
• The expiration date for these stock options is May 29, 2035.
• Following this transaction, Ms. Patel beneficially owns 9,174 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a standard compensation practice that aligns director interests with shareholders, without any negative implications or unusual events.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, reflecting ongoing commitment and participation in the company's governance.

Future Outlook

The future outlook for the granted options involves their vesting on the earlier of May 29, 2026, or the next annual meeting of stockholders, subject to the director's continued service. The options have a long-term expiration date of May 29, 2035, providing a significant window for potential exercise.

Management Comments

• The filing was signed by Michelle Gilson, as Attorney-in-Fact for Kavita Patel.

Industry Context

This transaction represents a routine compensation event for a director in a publicly traded biotechnology company. Granting stock options is a common practice across the industry to attract and retain qualified board members and align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in the biotechnology and pharmaceutical industries, similar to how companies like Gilead Sciences, Amgen, or Biogen compensate their non-employee directors.
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is typical for such equity awards, ensuring retention and commitment.
• The exercise price being set at the market price on the grant date is also a common industry standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of 9,174 stock options to Kavita Patel, a Director of Arcellx, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also aims to align the director's interests with long-term shareholder value.
• Director (Kavita Patel): Receives equity-based compensation, incentivizing continued service and performance aligned with the company's success.

Next Steps

• The stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, provided the director continues to serve.

Key Dates

Keywords

Arcellx, ACLX, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Corporate Governance